Effects of Antibiotics on Shiga Toxin 2 Production and Bacteriophage Induction by Epidemic Escherichia coli O104:H4 Strain

ABSTRACT The role of antibiotics in treatment of enterohemorrhagic Escherichia coli (EHEC) infections is controversial because of concerns about triggering hemolytic-uremic syndrome (HUS) by increasing Shiga toxin (Stx) production. During the recent large EHEC O104:H4 outbreak, antibiotic therapy was indicated for some patients. We tested a diverse panel of antibiotics to which the outbreak strain is susceptible to interrogate the effects of subinhibitory antibiotic concentrations on induction of stx2-harboring bacteriophages, stx2 transcription, and Stx2 production in this emerging pathogen. Ciprofloxacin significantly increased stx2-harboring phage induction and Stx2 production in outbreak isolates (P values of <0.001 to <0.05), while fosfomycin, gentamicin, and kanamycin insignificantly influenced them (P > 0.1) and chloramphenicol, meropenem, azithromycin, rifaximin, and tigecycline significantly decreased them (P ≤ 0.05). Ciprofloxacin and chloramphenicol significantly upregulated and downregulated stx2 transcription, respectively (P < 0.01); the other antibiotics had insignificant effects (P > 0.1). Meropenem, azithromycin, and rifaximin, which were used for necessary therapeutic or prophylactic interventions during the EHEC O104:H4 outbreak, as well as tigecycline, neither induced stx2-harboring phages nor increased stx2 transcription or Stx2 production in the outbreak strain. These antibiotics might represent therapeutic options for patients with EHEC O104:H4 infection if antibiotic treatment is inevitable. We await further analysis of the epidemic to determine if usage of these agents was associated with an altered risk of developing HUS.

[1]  J. Knobloch,et al.  Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4. , 2012, JAMA.

[2]  C. Hedberg,et al.  Antibiotic Treatment of Escherichia coli O157 Infection and the Risk of Hemolytic Uremic Syndrome, Minnesota , 2012, The Pediatric infectious disease journal.

[3]  Matthias Greiner,et al.  German outbreak of Escherichia coli O104:H4 associated with sprouts. , 2011, The New England journal of medicine.

[4]  Klaus Stark,et al.  Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. , 2011, The New England journal of medicine.

[5]  K. Titlestad,et al.  Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study , 2011, The Lancet.

[6]  A. Mellmann,et al.  Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. , 2011, The Lancet. Infectious diseases.

[7]  James H. Bullard,et al.  Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany. , 2011, The New England journal of medicine.

[8]  J. Rothberg,et al.  Prospective Genomic Characterization of the German Enterohemorrhagic Escherichia coli O104:H4 Outbreak by Rapid Next Generation Sequencing Technology , 2011, PloS one.

[9]  Snedeker,et al.  The new face of enterohaemorrhagic Escherichia coli infections. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[10]  Elias A. Rahal,et al.  Role of rifampicin in limiting Escherichia coli O157:H7 Shiga-like toxin expression and enhancement of survival of infected BALB/c mice. , 2011, International journal of antimicrobial agents.

[11]  A. Mellmann,et al.  Chromosomal instability in enterohaemorrhagic Escherichia coli O157:H7: impact on adherence, tellurite resistance and colony phenotype , 2011, Molecular microbiology.

[12]  A. Weiss,et al.  Different Classes of Antibiotics Differentially Influence Shiga Toxin Production , 2010, Antimicrobial Agents and Chemotherapy.

[13]  Andrzej Niemierko,et al.  Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. , 2010, JAMA.

[14]  R. Mutters,et al.  In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: Tigecycline Evaluation and Surveillance Trial 2004 to 2007 ☆ , 2009 .

[15]  H. Dupont,et al.  Pretreatment of Epithelial Cells with Rifaximin Alters Bacterial Attachment and Internalization Profiles , 2009, Antimicrobial Agents and Chemotherapy.

[16]  John-hwa Lee,et al.  Antimicrobials effective for inhibition of enterohaemorrhagic Escherichia coli strains O26, O111, and O157 and their effects on Shiga toxin releases. , 2009, Journal of microbiology and biotechnology.

[17]  P. Tarr,et al.  Acute bloody diarrhea: a medical emergency for patients of all ages. , 2009, Gastroenterology.

[18]  S. Tzipori,et al.  Gnotobiotic piglet infection model for evaluating the safe use of antibiotics against Escherichia coli O157:H7 infection. , 2009, The Journal of infectious diseases.

[19]  A. Mellmann,et al.  Analysis of Collection of Hemolytic Uremic Syndrome–associated Enterohemorrhagic Escherichia coli , 2008, Emerging infectious diseases.

[20]  S. Persson,et al.  Subtype-Specific Suppression of Shiga Toxin 2 Released from Escherichia coli upon Exposure to Protein Synthesis Inhibitors , 2008, Journal of Clinical Microbiology.

[21]  M. J. Pons,et al.  In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler's diarrhea. , 2007, Diagnostic microbiology and infectious disease.

[22]  M. Falagas,et al.  Old antibiotics for infections in critically ill patients , 2007, Current opinion in critical care.

[23]  C. Walker,et al.  Rifaximin Does Not Induce Toxin Production or Phage-Mediated Lysis of Shiga Toxin-Producing Escherichia coli , 2007, Antimicrobial Agents and Chemotherapy.

[24]  Clinical,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : Approved standard , 2006 .

[25]  H. Karch,et al.  Enterohaemorrhagic Escherichia coli in human medicine. , 2005, International journal of medical microbiology : IJMM.

[26]  V. Wendisch,et al.  Regulation of type 1 fimbriae synthesis and biofilm formation by the transcriptional regulator LrhA of Escherichia coli. , 2005, Microbiology.

[27]  H. Dupont,et al.  Rifaximin: In vitro and in vivo Antibacterial Activity – A Review , 2005, Chemotherapy.

[28]  P. Tarr,et al.  Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome , 2005, The Lancet.

[29]  P. Murdoch,et al.  The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[31]  C. Harwood,et al.  Toxin gene expression by shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response. , 2000, Emerging infectious diseases.

[32]  Craig S. Wong,et al.  The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. , 2000, The New England journal of medicine.

[33]  M. Waldor,et al.  Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. , 2000, The Journal of infectious diseases.

[34]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[35]  H. Karch,et al.  Transduction of Enteric Escherichia coli Isolates with a Derivative of Shiga Toxin 2-Encoding Bacteriophage φ3538 Isolated from Escherichia coli O157:H7 , 1999, Applied and Environmental Microbiology.

[36]  H. Karch,et al.  Strain-Specific Differences in the Amount of Shiga Toxin Released from Enterohemorrhagic Escherichia coli O157 following Exposure to Subinhibitory Concentrations of Antimicrobial Agents , 1998, European Journal of Clinical Microbiology and Infectious Diseases.

[37]  B. Bell,et al.  Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. , 1997, Pediatrics.

[38]  D. Acheson,et al.  Regulation of the Shiga-like toxin II operon in Escherichia coli , 1996, Infection and immunity.

[39]  G. Delage,et al.  Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis. , 1992, The Journal of pediatrics.

[40]  H. Karch,et al.  Growth of Escherichia coli in the presence of trimethoprim-sulfamethoxazole facilitates detection of Shiga-like toxin producing strains by colony blot assay , 1986 .